Analyst Ratings for ResMed
Analysts have provided the following ratings for ResMed (NYSE:RMD) within the last quarter:
10 Biggest Price Target Changes For Monday
Citigroup cut PVH Corp. (NYSE: PVH) price target from $94 to $73. PVH shares fell 0.7% to close at $71.96 on Friday.
A Peek Into The Markets: US Stock Futures Signal Higher Start On Wall Street
Pre-open movers
U.S. stock futures traded higher in early pre-market trade after the Nasdaq tumbled over 300 points in the previous session despite better-than-expected jobs report for May.
RBC Capital Upgrades ResMed to Outperform, Raises Price Target to $244
RBC Capital upgrades ResMed (NYSE:RMD) from Sector Perform to Outperform and raises the price target from $233 to $244.
If You Invested $100 In Resmed 5 Years Ago, Here’s How Much You Would Have Today
ResMed (NYSE:RMD) has outperformed the market over the past 5 years by 12.16% on an annualized basis producing an average annual return of 23.39%. Currently, ResMed has a market capitalization of $30.35 billion.
What 3 Analyst Ratings Have To Say About ResMed
Over the past 3 months, 3 analysts have published their opinion on ResMed (NYSE:RMD) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.
ResMed Q3 Adj. EPS $1.32 Misses $1.42 Estimate, Sales $864.50M Miss $897.04M Estimate
ResMed (NYSE:RMD) reported quarterly earnings of $1.32 per share which missed the analyst consensus estimate of $1.42 by 7.04 percent. This is a 1.54 percent increase over earnings of $1.30 per share from the same period
What 5 Analyst Ratings Have To Say About ResMed
ResMed (NYSE:RMD) has observed the following analyst ratings within the last quarter:
